DISCO Pharmaceuticals is a company that specializes in developing a comprehensive cartography of the cancer cell surface to identify new druggable targets. They use their proprietary surfaceome discovery technology to unlock the entire cancer cell surface at scale, enabling the identification of protein communities and unlocking comprehensive target information that standard proteomics, genome, or transcriptome sequencing cannot provide.